← All trials
NCT05131386
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 28, 2021
- Primary completion
- Jul 28, 2024
- Completion date
- Jul 28, 2024
- First posted
- Nov 23, 2021
- Last posted
- Nov 23, 2021
- Enrollment
- 85
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Grupo Espanol de Investigacion en SarcomasLead sponsor
- Universidad Autonoma de BarcelonaOverall official - principal investigator
- University of BarcelonaOverall official - principal investigator
- University of Las Palmas de Gran CanariaOverall official - principal investigator
- Universidad Complutense de MadridOverall official - principal investigator
- Autonomous University of MadridOverall official - principal investigator
- Hospital General Universitario Gregorio MarañonOverall official - principal investigator
- Universidad Autonoma de MadridStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.